Results from the HCV SPRINT-1 study will be submitted for presentation at a major medical conference later this year.
About Boceprevir Phase III Studies
The boceprevir Phase III studies are expected to begin enrolling patients this summer. For more information about the Phase III study of boceprevir in treatment-nave patients, known as HCV SPRINT-2, and the Phase III study in patients who failed prior treatment, known as HCV RESPOND-2, please visit http://www.clinicaltrials.gov, search term boceprevir.
About Hepatitis C
Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and Europe, and the most common form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe.
In the United States, PEGINTRON is indicated for use alone or with ribavirin for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.
Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL
Alpha interferons, including PEGINTRON and INTRON(R) A, may cause or
aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic,
and infectious disorders. Patients should be monitored closely with
periodic clinical and laboratory evaluations. Patients with persistently
severe or worsening signs or symptoms of these conditions should be
withdrawn from therapy
|SOURCE Schering-Plough Corporation|
Copyright©2008 PR Newswire.
All rights reserved